TTNP Archives - Page 3 of 4

Developments

Kate DeVarney joins Titan Pharma’s Board

Kate DeVarney, EVP and CSO of Titan Pharmaceuticals (NASDAQ:TTNP), was elected to the board at the company’s annual meeting. Dr. DeVarney, a clinical neuropsychologist by training, joined Titan in January...

December 30, 2019

Markets

Maxim ups Titan Pharma to buy with PT of $1

Maxim Group upgraded Titan Pharmaceuticals (NASDAQ:TTNP) to “buy” from “hold,” establishing a $1 price target as the company has raised capital and removed a financing overhang. The stock was quoted at 20 cents in...

October 23, 2019

Developments

Titan Pharma to present two Probuphine posters at conference

Titan Pharmaceuticals (NASDAQ:TTNP) will present two posters on its buprenorphine implant, Probuphine, at the tenth American Conference of Pharmacometrics. Probuphine is a subdermal implant that provides six-month...

October 22, 2019

Developments

Titan Pharma gets second year of NIDA funding for nalmefene implant development

The National Institutes of Health’s National Institute on Drug Abuse (NIDA) approved $6.1-million in second-year funding for Titan Pharmaceuticals‘ (NASDAQ:TTNP) development of a nalmefene implant. Titan is using...

September 18, 2019

Developments

Knight expands reimbursement for Titan Pharma’s Probuphine in Canada

Knight Therapeutics (TSX:GUD) reached agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for a letter of intent covering reimbursement of Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine, the first...

August 6, 2019

Developments

Titan Pharma receives positive EU CHMP opinion for Probuphine (“Sixmo”)

Titan Pharmaceuticals (NASDAQ:TTNP) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for marketing authorization of Sixmo, the brand name for...

April 29, 2019

Developments

Titan Pharma’s Probuphine implant to treat OUD continues to gain national media attention

Channel 8’s Daytime aired nationally an interview with two senior executives of Titan Pharmaceuticals (NASDAQ:TTNP) – Dane Hallberg, EVP and chief commercial officer, and Dr. Kate DeVarney, EVP and chief scientific...

April 26, 2019

Developments

Titan Pharma’s Probuphine now in use across Canada

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant for opioid use disorder is now being used in patients across Canada. Approved by Health Canada in April 2018, Probuphine is the only subdermal implant designed to...

April 15, 2019

Developments

Titan Pharma in pact with AppianRx for comprehensive Probuphine patient support services

Titan Pharmaceuticals (NASDAQ:TTNP) executed a service agreement with AppianRx, a specialty healthcare solutions company, to provide a full suite of patient support services related to Titan’s Probuphine implant, a...

March 28, 2019

Developments

Titan Pharma in pact with AllianceRx Walgreens Prime to expand patient access to Probuphine

Titan Pharmaceuticals (NASDAQ:TTNP) entered a specialty pharmacy distribution and services agreement with AllianceRx Walgreens Prime to expand patient access to its Probuphine six-month implant for the maintenance...

February 25, 2019

Tag - TTNP

Kate DeVarney joins Titan Pharma’s Board

Maxim ups Titan Pharma to buy with PT of $1

Titan Pharma to present two Probuphine posters at conference

Titan Pharma gets second year of NIDA funding for nalmefene implant development

Knight expands reimbursement for Titan Pharma’s Probuphine in Canada

Titan Pharma receives positive EU CHMP opinion for Probuphine (“Sixmo”)

Titan Pharma’s Probuphine implant to treat OUD continues to gain national media attention

Titan Pharma’s Probuphine now in use across Canada

Titan Pharma in pact with AppianRx for comprehensive Probuphine patient support services

Titan Pharma in pact with AllianceRx Walgreens Prime to expand patient access to Probuphine

General

More